Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have received an average recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.43.

A number of equities analysts recently commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. B. Riley reiterated a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners began coverage on Trevi Therapeutics in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a report on Tuesday, October 22nd.

Insider Activity

In other news, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. This trade represents a 4.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 21,595 shares of company stock valued at $64,886. Company insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its holdings in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after buying an additional 7,902 shares during the period. MAI Capital Management boosted its stake in shares of Trevi Therapeutics by 0.7% in the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after buying an additional 8,789 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new position in Trevi Therapeutics during the first quarter worth $47,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $2.75 on Wednesday. The firm has a market capitalization of $211.39 million, a P/E ratio of -6.25 and a beta of 1.01. The stock’s fifty day moving average is $3.14 and its two-hundred day moving average is $2.91. Trevi Therapeutics has a fifty-two week low of $0.97 and a fifty-two week high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the previous year, the firm posted ($0.08) earnings per share. On average, equities analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.